Interviews with a U.S. senator, congressional staffers, AI companies and interest groups show there are a number of options under discussion.
It's uncertain which approaches will win out, but some in the business community, including IBM and the U.S. Chamber of Commerce, favor the approach that only regulates critical areas like medical diagnoses, which they call a risk-based approach. The AI hype has led to a flurry of meetings, including a White House visit this month by the CEOs of OpenAI, its backer Microsoft Corp, and Alphabet Inc. President Joe Biden met with the CEOs."Staff broadly across the House and the Senate have basically woken up and are all being asked to get their arms around this," said Jack Clark, co-founder of high-profile AI startup Anthropic, whose CEO also attended the White House meeting.
Schumer's proposed plan requires independent experts to test new AI technologies prior to their release. It also calls for transparency and providing the government with data it needs to avert harm.The risk-based approach means AI used to diagnose cancer, for example, would be scrutinized by the Food and Drug Administration, while AI for entertainment would not be regulated. The European Union has moved toward passing similar rules.